Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients

Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients

This study aimed to determine the clinical impact of CD25+/CD123+ coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were assesse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in Hematology 2020, Vol.2020 (2020), p.1-5
Hauptverfasser: Ibrahim, L., Khaled, Nada, El Agdar, Mohamed, Aref, Salah, El-Ghonemy, M.
Format: Artikel
Sprache:eng
Schlagworte:
Acute lymphocytic leukemia
Adults
Antigens
Bone marrow
Chemotherapy
Chromosomes
Cloning
Comparative analysis
Cytokines
Ethylenediaminetetraacetic acid
Kinases
Leukemia
Medical equipment and supplies industry
Medical prognosis
Medical test kit industry
Patients
Software
Stem cells
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study aimed to determine the clinical impact of CD25+/CD123+ coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were assessed using flow cytometry. CD25+/CD123+ coexpression was detected in 40/120 B-ALL patients (33.3%). All B-ALL patients showed CD25+/CD123+ coexpression had lower induction of remission response and shorter overall survival as compared to B-ALL cases lacking coexpression. In conclusion, CD25+/CD123+ positive coexpression is a reliable flow cytometry marker for prediction of the outcome of adult B-ALL patients and could be used as a novel parameter for risk stratification of adult B-ALL cases.
ISSN:1687-9104
1687-9112
DOI:10.1155/2020/9545717